Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.36% and Operating profit at -47.33% over the last 5 years
2
The company has declared negative results for the last 4 consecutive quarters
3
With ROE of 3.97%, it has a very expensive valuation with a 4.03 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 98,065 Million (Mid Cap)
162.00
NA
0.00%
-0.08
3.71%
46.61
Revenue and Profits:
Net Sales:
193 Million
(Quarterly Results - Mar 2026)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.7%
0%
-23.7%
6 Months
9.97%
0%
9.97%
1 Year
37.07%
0%
37.07%
2 Years
46.19%
0%
46.19%
3 Years
17.81%
0%
17.81%
4 Years
73.41%
0%
73.41%
5 Years
-46.94%
0%
-46.94%
Xiangyu Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.36%
EBIT Growth (5y)
-47.33%
EBIT to Interest (avg)
60.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.30
Tax Ratio
4.11%
Dividend Payout Ratio
35.51%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.10%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
162
Industry P/E
Price to Book Value
5.71
EV to EBIT
964.35
EV to EBITDA
223.73
EV to Capital Employed
6.23
EV to Sales
14.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.65%
ROE (Latest)
3.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
193.10
186.00
3.82%
Operating Profit (PBDIT) excl Other Income
20.80
26.30
-20.91%
Interest
2.20
4.50
-51.11%
Exceptional Items
0.00
0.00
Consolidate Net Profit
24.90
22.40
11.16%
Operating Profit Margin (Excl OI)
107.90%
63.90%
4.40%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 3.82% vs 9.99% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 11.16% vs -42.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
764.00
740.00
3.24%
Operating Profit (PBDIT) excl Other Income
83.00
96.00
-13.54%
Interest
10.30
5.90
74.58%
Exceptional Items
-1.20
-1.80
33.33%
Consolidate Net Profit
76.00
102.90
-26.14%
Operating Profit Margin (Excl OI)
25.10%
73.00%
-4.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.24% vs 0.45% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -26.14% vs -54.93% in Dec 2024
About Xiangyu Medical Co., Ltd. 
Xiangyu Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






